U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07393113) titled 'CLarifying ABCB1's Role in Alzheimer's Disease' on Jan. 19.
Brief Summary: Alzheimer's disease is biologically defined by the accumulation of amyloid beta and tau protein, identified using cerebrospinal fluid biomarkers. The ABCB1 gene, which encodes P-glycoprotein involved in amyloid beta efflux across the blood-brain barrier, may influence Alzheimer's disease risk. We hypothesize that certain functional ABCB1 polymorphisms impair amyloid beta clearance, thereby promoting the development of biologically defined Alzheimer's disease.
Study Start Date: Oct. 25, 2023
Study Type: OBSERVATIONAL
Condition:
Alzheimer Disease
Interventi...